Evaluating the cost effectiveness of newer psychotropic medications

American Journal of Managed Care

Volumn 3, Issue FEB, 1997, Pages

  Viale, Gary L ^a  

^a Central Mental Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PSYCHOTROPIC AGENT;

ARTICLE; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; EVALUATION; HUMAN; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; STANDARD; STATISTICS; UNITED STATES;

CALIFORNIA; COST-BENEFIT ANALYSIS; DRUG COSTS; EVALUATION STUDIES; HUMANS; PATIENT COMPLIANCE; PSYCHOTROPIC DRUGS; RETROSPECTIVE STUDIES;

EID: 0031061566     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (7)

1. Andreasen NC. Assessment issues and the cost of schizophrenia. Schizophr Bull 1991; 17:475-481.
2. National Advisory Mental Health Council. Health care reform for Americans with severe mental illnesses. Am J Psychiatry 1993;150:1447-1465.
3. Caton CLM, Koh SP, Fleiss JL, et al. Rehospitalization in chronic schizophrenia. J Nerv Ment Dis 1985;173:139-148.
4. Cavallero R, Smeraldi E. Antipsychotic-induced tardive dyskinesia: Recognition, prevention and management. CNS Drugs (New Zealand) 1995;4:278-293.
5. Addington DE, Jones B, Bloom D, et al. Reduction in hospital days in chronic schizophrenic patients treated with risperidone: A retrospective study. Clin Ther 1993;15:917-926.
6. Lindström E, Eriksson B, Hellgren A, et al. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther 1995;17:402-412.
7. Albright PS, Livingstone S, Keegan DL, et al. Reduction of healthcare resource utilisation and costs following the use of risperidone for patients with schizophrenia previously treated with standard antipsychotic therapy: A retrospective analysis using the Saskatchewan Health linkable databases. Clin Drug Invest 1996;11:289-299.